Valsartan's third payment deadline has expired

The NHIS calls for payment until end of last year

36 pharmaceutical companies filed a lawsuit without debt last November

Determine justification for government actions in court

The third payment deadline for the Valsartan damages claim urged by health authorities has ended.

 

Most of the companies that did not pay the compensation were refused to pay.

 

The health authorities say they will continue to incentivize payments, but a lawsuit filed by pharmaceutical companies will conclude the legitimacy of government action.

 

According to the industry on the 7th, the third payment deadline for the Valsartan indemnity claims by the National Health Insurance service has expired on December 31 last year.

 

In October last year, the NHIS asked for 69 drug companies to pay ₩2030 million in compensation.

 

It is a follow-up in accordance with the Ministry of Health and Welfare's decision to return the amount of money invested in pharmacies since the outbreak of the impurity Valsartan issue in 2018 for the remainder of the prescription.

 

The NHIS sent the first reminder to the pharmaceutical companies that did not pay the compensation, by last October 31.

 

Again, due to low payment rates, the NHIS sent a second reminder last December.

 

In order to increase the collection rate, three payment deadlines were given.

 

However, most companies that did not pay the initial deadline were reportedly refused to pay.

 

According to data submitted to the Democratic Party's lawmakers by In-soon Nam last November, 26 pharmaceutical companies paid ₩440 million in compensation.

 

The payment rate was only 21.5%.

 

Pharmaceutical companies refused to pay about 80% of the proceeds.

 

The company has already entered a lawsuit with the NHIS, especially those with large amounts of compensation.

 

Pharmaceutical companies filed a lawsuit to confirm the absence of debt against the National Health Insurance Service on November 27 of last year.

 

It preemptively filed a lawsuit stating that it was not responsible for Valsartan damages claimed by the NHIS.

 

Companies involved in litigation include JW PHARMACEUTICAL CORPORATION , JW SHINYAK CORPORATION, SK Chemicals, Khunil Pharmaceutical, Kwang Dong Pharmaceutical , Guju Pharmaceutical, Kukje Pharmaceutical, Nexpharm Korea, Dasan Pharmaceutical, Daewoo Pharmaceutical, Daewon Pharmaceutical, DAE HWA Pharmaceutical Co., Ltd., DongKoo Bio Pharmaceutical, Mother's Pharmaceutical, MyungMoon Pharm.

 

Co., Ltd., BINEX.CO.LTD, Samik Pharmaceutical Co., Ltd., SAMIL PHARMACEUTICAL CO.,LTD , CMG Pharm, Ajou Pharm, Unimed Pharm, Inist Bio Pharm, Eden Pharma, Reyon Pharm, Chong Kun Dang, Jinyang Pharm, Terragen Etex, Hana Pharm, Korea Kolmar, Hutecs, Hanlim Pharmaceuticals, Hanwha Pharmaceuticals, Whanin Pharmaceuticals, Huons, Huons Medicare, etc.

 

Most companies with large amounts of compensation were involved in litigation.

 

LG Chemical did not participate in the lawsuit among six companies, including Daewon Pharm, Hutecs, LG Chemical, Hanlim Pharm, JW SHINYAK CORPORATION, and Korea Kolmar.

 

Pharmaceutical companies are claiming that they are not responsible for Valsartan claims claimed by the government.

 

Pharmaceutical companies stress that there are no manufacturing and design flaws with impurity Valsartan.

 

Carcinogen N-nitrosodimethylamine (NDMA), detected in Valsartan issue, is a hazardous substance in the Valsartan raw material that has no standard.

 

Neither governments nor pharmaceutical companies were aware of the risk of NDMA detection in Valsartan.

 

According to the Product Liability Act, it is clear that if the manufacturer proves that a defect was not found at the level of science and technology at the time the manufacturer supplied the product, it would be liable for damages.